Cargando…
Dolutegravir plus lamivudine for maintenance of HIV viral suppression in adults with and without historical resistance to lamivudine: 48-week results of a non-randomized, pilot clinical trial (ART-PRO)
BACKGROUND: We investigated the efficacy of a switch to dolutegravir plus lamivudine in aviremic individuals without evidence of persistent lamivudine resistance-associated mutations in baseline proviral DNA population sequencing. METHODS: Open-label, single-arm, 48-week pilot trial. HIV-1 infected...
Autores principales: | De Miguel, Rosa, Rial-Crestelo, David, Dominguez-Dominguez, Lourdes, Montejano, Rocío, Esteban-Cantos, Andrés, Aranguren-Rivas, Paula, Stella-Ascariz, Natalia, Bisbal, Otilia, Bermejo-Plaza, Laura, Garcia-Alvarez, Mónica, Alejos, Belén, Hernando, Asunción, Santacreu-Guerrero, Mireia, Cadiñanos, Julen, Mayoral, Mario, Castro, Juan Miguel, Moreno, Victoria, Martin-Carbonero, Luz, Delgado, Rafael, Rubio, Rafael, Pulido, Federico, Arribas, José Ramón |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7225620/ https://www.ncbi.nlm.nih.gov/pubmed/32408111 http://dx.doi.org/10.1016/j.ebiom.2020.102779 |
Ejemplares similares
-
Long-term Evaluation of Residual Viremia in a Clinical Trial of Dolutegravir Plus Lamivudine as Maintenance Treatment for Participants With and Without Prior Lamivudine Resistance
por: De Miguel Buckley, Rosa, et al.
Publicado: (2022) -
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice
por: Suárez-García, Inés, et al.
Publicado: (2023) -
Dolutegravir And Lamivudine Combination For The Treatment Of HIV-1 Infection
por: Zamora, Francis J, et al.
Publicado: (2019) -
Real-World Effectiveness, Tolerability, and Safety of Dolutegravir/Lamivudine in Korea
por: Lee, Ki Hyun, et al.
Publicado: (2022) -
Dolutegravir plus lamivudine versus efavirenz plus tenofovir disoproxil fumarate and lamivudine in antiretroviral-naive adults with HIV-1 infection
por: Deng, Lisi, et al.
Publicado: (2022)